Cholesterol Biosynthesis and the Mevalonate Pathway - Biochemistry

1. A patient with Smith-Lemli-Opitz syndrome has a deficiency in 7-dehydrocholesterol reductase, the final enzyme in cholesterol biosynthesis. Plasma analysis shows elevated 7-dehydrocholesterol levels but also reveals a 3-fold increase in lanosterol compared to normal individuals. Given that lanosterol is an intermediate much earlier in the pathway, what mechanism best explains this unexpected accumulation?
   Answer: Loss of cholesterol end-product inhibition triggers SREBP-2 activation, increasing flux into the pathway while the final step blockade causes backup of intermediates including lanosterol In Smith-Lemli-Opitz syndrome, the block in cholesterol synthesis reduces cellular cholesterol levels, which relieves end-product inhibition and activates SREBP-2. This increases transcription of all cholesterol biosynthetic enzymes, driving more flux into the pathway. However, since the final step is blocked, intermediates including both 7-dehydrocholesterol (immediately upstream of the block) and lanosterol (further upstream) accumulate because the pathway is essentially 'backed up' like a traffic jam. Choice A is incorrect because 7-dehydrocholesterol doesn't inhibit lanosterol demethylase. Choice B is wrong because the defect is downstream, not in squalene enzymes. Choice D is incorrect because 7-dehydrocholesterol reductase doesn't provide allosteric regulation to upstream enzymes.
2. During fasting conditions, liver cells show decreased cholesterol synthesis despite normal HMG-CoA reductase protein levels. Analysis reveals that AMPK is highly activated and phosphorylates HMG-CoA reductase at Ser871. In cell-free enzyme assays, phosphorylated HMG-CoA reductase shows 15% activity compared to the dephosphorylated form. However, when fasted liver homogenates are treated with alkaline phosphatase, HMG-CoA reductase activity only recovers to 35% of fed state levels. What additional factor likely contributes to the persistent inhibition?
   Answer: Fasting conditions reduce NADPH availability from the pentose phosphate pathway, limiting the reductase reaction even when the enzyme is dephosphorylated and fully active During fasting, glucose metabolism decreases, reducing flux through the pentose phosphate pathway, which is the primary source of NADPH. HMG-CoA reductase requires NADPH as a cofactor for the reduction of HMG-CoA to mevalonate. Even when the enzyme is dephosphorylated and theoretically active, insufficient NADPH availability limits the reaction rate. This explains why activity only partially recovers after phosphatase treatment. Choice B is incorrect because PKA doesn't directly phosphorylate HMG-CoA reductase. Choice C is wrong because acetyl-CoA doesn't compete with HMG-CoA at the active site. Choice D is incorrect because Insig activation during fasting is primarily sterol-dependent and wouldn't explain the partial recovery after dephosphorylation.
3. Biochemists studying mevalonate pathway regulation discover that phosphomevalonate kinase is inhibited by geranyl pyrophosphate (GPP) with a $K_i$ of 15 μM, while the enzyme's $K_m$ for phosphomevalonate is 25 μM. In rapidly growing cells where GPP concentrations reach 40 μM, this inhibition reduces the enzyme activity to approximately 30% of maximum. What is the most likely physiological significance of this regulatory mechanism?
   Answer: It provides negative feedback control to prevent overproduction of mevalonate-derived metabolites when sufficient isoprenoid precursors are already available for cellular needs When you encounter enzyme regulation questions involving feedback inhibition, focus on identifying the relationship between the inhibitor and its position in the metabolic pathway. This question tests your understanding of negative feedback control in the mevalonate pathway. Geranyl pyrophosphate (GPP) is a downstream product of the mevalonate pathway, and it's inhibiting phosphomevalonate kinase, an upstream enzyme. This is classic negative feedback inhibition. When GPP concentrations are high (40 μM, well above the $K_i$ of 15 μM), it signals that sufficient isoprenoid products have been made, so the pathway should slow down. The 70% reduction in enzyme activity (to 30% maximum) demonstrates potent inhibition that prevents wasteful overproduction of mevalonate-derived compounds. Answer D correctly identifies this as negative feedback control preventing overproduction when adequate isoprenoid precursors exist. This is the fundamental principle of metabolic regulation. Answer A focuses on ATP conservation, but feedback inhibition primarily prevents product overaccumulation, not energy conservation. Answer B suggests this regulates branching between different isoprenoid products, but phosphomevalonate kinase acts early in the pathway before major branching occurs. Answer C specifically mentions cholesterol synthesis coordination, but GPP inhibition affects the entire mevalonate pathway, not just cholesterol production. Remember: negative feedback inhibition occurs when a downstream product inhibits an upstream enzyme. Look for the inhibitor's position relative to the enzyme in the pathway – if the inhibitor comes after the enzyme in the metabolic sequence, it's likely negative feedback control.
4. In a well-fed state, high levels of glucose lead to increased flux through glycolysis and the citric acid cycle, producing an abundance of mitochondrial citrate. How does this high citrate level promote cholesterol biosynthesis in the cytosol?
   Answer: Citrate is transported to the cytosol and cleaved by ATP-citrate lyase to generate the cytosolic acetyl-CoA required for the pathway. Acetyl-CoA, the building block for cholesterol, is produced in the mitochondria. However, cholesterol synthesis occurs in the cytosol. Acetyl-CoA cannot cross the inner mitochondrial membrane directly. Instead, it condenses with oxaloacetate to form citrate. When energy levels are high, citrate accumulates and is transported to the cytosol via the citrate transporter. In the cytosol, the enzyme ATP-citrate lyase cleaves citrate back into acetyl-CoA and oxaloacetate, providing the necessary substrate for cholesterol and fatty acid synthesis.
5. In a metabolic flux analysis experiment, liver cells are incubated with $^{13}C_2$-acetate, and the incorporation into various metabolites is measured after 2 hours. When farnesyl pyrophosphate (FPP) synthesis is specifically blocked by a selective inhibitor, researchers observe that $^{13}C$ labeling in cholesterol drops to 5% of control levels, but labeling in CoQ10 (ubiquinone) remains at 65% of control. What explains this differential effect?
   Answer: CoQ10 synthesis can utilize geranyl-PP directly without requiring FPP, while cholesterol synthesis has an absolute requirement for FPP-derived squalene formation CoQ10 (ubiquinone) synthesis requires a 10-unit isoprenoid side chain that can be synthesized directly from geranyl pyrophosphate (GPP) and isopentenyl pyrophosphate without requiring farnesyl pyrophosphate. In contrast, cholesterol synthesis has an absolute requirement for FPP because two FPP molecules must condense to form squalene, which is then cyclized to cholesterol. When FPP synthesis is blocked, cholesterol production is severely impaired, but CoQ10 can still be made using the alternative GPP pathway. Choice A is incorrect because there are no known mevalonate-independent pathways for CoQ10. Choice B misunderstands the stoichiometry - cholesterol actually requires 2 FPP molecules. Choice D is incorrect because salvage pathways don't significantly contribute to isoprenoid biosynthesis in this timeframe.
6. Researchers studying cholesterol homeostasis create a cell line with a temperature-sensitive mutation in SREBP cleavage-activating protein (SCAP). At 37°C, SCAP is functional, but at 42°C, it loses activity within 30 minutes. When cells are shifted from 37°C to 42°C in the presence of cyclohexamide (protein synthesis inhibitor), HMG-CoA reductase activity decreases to 20% of initial levels within 3 hours. What is the primary mechanism responsible for this decrease?
   Answer: Loss of SCAP function prevents SREBP-2 processing, eliminating transcriptional activation of HMG-CoA reductase genes and causing enzyme levels to decrease as existing proteins undergo normal turnover When you encounter questions about cholesterol homeostasis and SREBP regulation, focus on the pathway from sterol sensing to gene transcription. The SREBP system controls cholesterol synthesis primarily through transcriptional regulation, not direct enzyme modification. SCAP (SREBP cleavage-activating protein) is essential for SREBP-2 processing and activation. Under low cholesterol conditions, SCAP escorts SREBP-2 from the ER to the Golgi, where proteases cleave SREBP-2 to release its active transcription factor domain. This active SREBP-2 then enters the nucleus and upregulates genes encoding cholesterol synthesis enzymes, including HMG-CoA reductase. When SCAP becomes inactive at 42°C, SREBP-2 cannot be processed and activated. Without functional SREBP-2 transcription factors, HMG-CoA reductase gene transcription stops. Since cyclohexamide blocks new protein synthesis (confirming the transcriptional mechanism), existing HMG-CoA reductase enzymes gradually disappear through normal protein turnover, explaining the 3-hour timeframe for activity to drop to 20%. Option A incorrectly invokes calcium-dependent proteases, which aren't part of the SREBP pathway. Option B mischaracterizes SCAP's function—it doesn't transport cholesterol but rather escorts SREBP-2 for processing. Option C suggests AMPK activation, but temperature-induced SCAP inactivation doesn't trigger AMPK, and the cyclohexamide experiment rules out this mechanism. Remember: SREBP regulation primarily controls cholesterol homeostasis through transcriptional control, not post-translational enzyme modifications. When you see SCAP/SREBP questions, think "gene expression" first.
7. A patient with familial hypercholesterolemia is treated with a combination of atorvastatin (HMG-CoA reductase inhibitor) and ezetimibe (cholesterol absorption inhibitor). After 6 weeks of treatment, plasma mevalonate levels are barely detectable, but cholesterol synthesis rates measured by $^{14}C$-acetate incorporation remain at 40% of pretreatment levels. What is the most likely explanation for this apparent paradox?
   Answer: Residual HMG-CoA reductase activity produces sufficient mevalonate below detection limits, while compensatory upregulation of downstream enzymes amplifies the remaining flux Even very low levels of HMG-CoA reductase activity can produce mevalonate below detection limits. The cell responds to cholesterol depletion by upregulating SREBP-2, which increases expression of all cholesterol biosynthetic enzymes downstream of HMG-CoA reductase. This coordinate upregulation can amplify the flux through the remaining functional enzyme, maintaining significant cholesterol synthesis even when mevalonate is undetectable. Choice A is incorrect because there are no known alternative pathways that bypass mevalonate. Choice C doesn't explain continued $^{14}C$-acetate incorporation. Choice D is wrong because the assay conditions would distinguish between cholesterol and ketone body synthesis.
8. A novel compound is discovered that specifically inhibits squalene synthase, the enzyme that condenses two farnesyl pyrophosphate molecules to form squalene. When cultured hepatocytes are treated with this inhibitor, researchers measure a 95% reduction in cholesterol synthesis but observe unexpected accumulation of several non-sterol isoprenoid compounds. Which of the following best explains the pattern of metabolite accumulation?
   Answer: Accumulated farnesyl-PP is redirected toward protein prenylation reactions and synthesis of coenzyme Q10, dolichol, and other essential isoprenoids that share common precursors When squalene synthase is inhibited, farnesyl pyrophosphate cannot be converted to squalene for cholesterol synthesis. The accumulated FPP is then redirected into alternative biosynthetic pathways that produce other essential isoprenoid compounds. These include protein prenylation (farnesylation and geranylgeranylation), coenzyme Q10 synthesis, dolichol synthesis for protein glycosylation, and other non-sterol isoprenoids. This metabolic rerouting explains the accumulation of these compounds. Choice B is incorrect because steroid hormones and bile acids are derived from cholesterol, not from alternative pathways. Choice C is wrong because there's no futile cycling in this pathway. Choice D is incorrect because the inhibitor is specific for squalene synthase and wouldn't cause allosteric effects on upstream enzymes.
9. Researchers studying cholesterol regulation in hepatocytes observe that when cells are incubated with 25-hydroxycholesterol (25-HC), HMG-CoA reductase protein levels decrease by 90% within 4 hours, but mRNA levels remain unchanged. Simultaneously, SREBP-2 processing is blocked even though ER cholesterol levels are normal. Which mechanism best accounts for these observations?
   Answer: 25-HC activates Insig proteins, which promote HMG-CoA reductase degradation and block SREBP-2 transport to the Golgi regardless of sterol sensor domain occupancy 25-hydroxycholesterol is a potent activator of Insig proteins (Insig-1 and Insig-2). Activated Insig proteins have two key functions: they promote ubiquitination and proteasomal degradation of HMG-CoA reductase (explaining the rapid protein loss without mRNA changes), and they bind to SCAP preventing SREBP-2 transport from ER to Golgi for processing. This dual mechanism allows 25-HC to suppress cholesterol synthesis even when ER cholesterol levels appear normal. Choice A is incorrect because 25-HC doesn't bind directly to HMG-CoA reductase and doesn't activate SCAP. Choice C is wrong because 25-HC doesn't significantly affect ATP levels. Choice D is incorrect because LXR activation wouldn't explain the direct effects on HMG-CoA reductase protein levels.

Start this quiz